Ceftazidime    (DrugBank: Ceftazidime)

1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis12

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
12 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-012575-10-SE
(EUCTR)
08/12/201604/10/2016Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis - TORPEDO-CFTrial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis - TORPEDO-CF Product Name: Ceftazidime
INN or Proposed INN: Ceftazidime
Other descriptive name: N/A
Product Name: Tobramycin
INN or Proposed INN: Tobramycin
Other descriptive name: N/A
Product Name: Ciprofloxacin
INN or Proposed INN: Ciprofloxacin
Other descriptive name: N/A
Product Name: Ciprofloxacin
INN or Proposed INN: Ciprofloxacin
Other descriptive name: N/A
University Hospitals Bristol NHS Foundation TrustUniversity of LiverpoolNot RecruitingFemale: yes
Male: yes
260Phase 4United Kingdom;Sweden
2EUCTR2016-001785-29-IE
(EUCTR)
15/08/201610/05/2016Study of the effects of combined treatment with the CFTR corrector ivacaftor and IV antibiotics on infection in CF.Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Kalydeco
INN or Proposed INN: IVACAFTOR
Trade Name: Ciprofloxacin
INN or Proposed INN: Ciprofloxacin
Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE
Product Name: Flucloxicillin
INN or Proposed INN: FLUCLOXACILLIN SODIUM
Trade Name: Fortum
INN or Proposed INN: CEFTAZIDIME
Product Name: Tobramycin
INN or Proposed INN: TOBRAMYCIN SULFATE
Trade Name: Meropenem
INN or Proposed INN: Meropenem
Other descriptive name: MEROPENEM
Trade Name: Colistin
INN or Proposed INN: COLISTIMETHATE SODIUM
St. Vincent's University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 4Ireland
3EUCTR2016-000398-19-BE
(EUCTR)
08/03/201609/02/2016Pilot study: pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem in blood and sputum of cystic fibrosis patients.Pilot study: pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem in blood and sputum of cystic fibrosis patients. - pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem Cystic fibrosis;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]Trade Name: Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie
INN or Proposed INN: Meropenem Fresenius Kabi
Other descriptive name: MEROPENEM TRIHYDRATE
Trade Name: Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie
INN or Proposed INN: Ceftazidim Fresenius Kabi
Other descriptive name: CEFTAZIDIME PENTAHYDRATE
Trade Name: Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
INN or Proposed INN: Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
Other descriptive name: PIPERACILLIN SODIUM
INN or Proposed INN: Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
Other descriptive name: TAZOBACTAM SODIUM
Trade Name: Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
INN or Proposed INN: Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
Other descriptive name: PIPERACILLIN SODIUM
INN or Proposed INN: Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
Other descriptive name: TAZOBACTAM SODIUM
Ghent UniversityNULLNot RecruitingFemale: yes
Male: yes
45Phase 4Belgium
4NCT02840136
(ClinicalTrials.gov)
February 201618/7/2016LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis PatientsOptimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and ValidationCystic FibrosisDrug: Piperacillin-tazobactam combination product;Drug: Meropenem;Drug: CeftazidimeUniversity GhentKing Baudouin Foundation;Belgische Vereniging voor Strijd tegen MucoviscidoseSuspended12 YearsN/AAll40N/ABelgium
5NCT02504827
(ClinicalTrials.gov)
September 201520/7/2015Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic FibrosisSteady-state Pharmacokinetics of Ceftazidime/Avibactam in CFCystic FibrosisDrug: Ceftazidime/avibactamUniversity of Southern CaliforniaNULLCompleted18 YearsN/AAll12Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02526004
(ClinicalTrials.gov)
January 201510/8/2015Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results StratifiedCystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results StratifiedCystic FibrosisDrug: Ceftazidime;Drug: TobramycinUniversity College CorkQueen's University, Belfast;Paris Descartes University;University of Dundee;University of Washington;University Hospital Heidelberg;Teagasc;Clininfo;GABO:mi;Papworth Hospital;Katholieke Universiteit Leuven;Assistance Publique - Hôpitaux de Paris;European UnionRecruiting16 Years80 YearsBoth252N/AIreland
7NCT01667094
(ClinicalTrials.gov)
September 201213/8/2012A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic FibrosisContinuous-infusion Anti-pseudomonal ß-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic FibrosisCystic FibrosisDrug: Intermittent, short infusion Ceftazidime;Drug: Continuous infusion Ceftazidime;Drug: Intermittent, short infusion Meropenem;Drug: Continuous infusion Meropenem;Drug: Intermittent, short infusion Ticarcillin-clavulanate;Drug: Continuous infusion Ticarcillin-clavulanate;Drug: Intermittent, short infusion Cefepime;Drug: Continuous infusion Cefepime;Drug: Continuous infusion Piperacillin tazobactam;Drug: Intermittent, short infusion Piperacillin tazobactamThe AlfredNULLActive, not recruiting18 YearsN/AAll50Phase 4Australia
8NCT01044719
(ClinicalTrials.gov)
January 201014/12/2009Duration of Antibiotics in Infective Exacerbations of Cystic FibrosisWhat Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas AeruginosaCystic FibrosisDrug: Ceftazidime;Drug: Tobramycin;Drug: MeropenemImperial College LondonNULLNot yet recruiting16 YearsN/ABoth240Phase 4United Kingdom
9EUCTR2009-014042-28-GB
(EUCTR)
16/10/200914/10/2010What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? - Duration of antibiotics in infective exacerbations of cystic fibrosisWhat duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? - Duration of antibiotics in infective exacerbations of cystic fibrosis Cystic FibrosisTrade Name: Meropenem
Product Name: Meropenem
INN or Proposed INN: Meropenem
Trade Name: Ceftazidime
Product Name: Ceftazidime
INN or Proposed INN: Ceftazidime
Trade Name: Tobramycin
Product Name: Tobramycin
INN or Proposed INN: Tobramycin
Imperial College, LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
240United Kingdom
10NCT00823238
(ClinicalTrials.gov)
July 200429/12/2008Comparison of Antibiotics for Pseudomonas in Early CFComparison of Antibiotics for Pseudomonas in Early CFCystic FibrosisDrug: ceftazidime and tobramycin;Drug: inhaled tobramycinUniversity of North Carolina, Chapel HillCystic Fibrosis Foundation TherapeuticsCompleted3 Months16 YearsBoth21Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00153634
(ClinicalTrials.gov)
March 20048/9/2005Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)Standard vs. Biofilm Susceptibility Testing in CFCystic Fibrosis;Chronic BronchitisDrug: IV amikacin;Drug: PO azithromycin;Drug: IV ceftazidime;Drug: PO ciprofloxacin;Drug: IV meropenem;Drug: IV piperacillin-tazobactam;Drug: IV ticarcillin-clavulanate;Drug: IV tobramycinSeattle Children's HospitalCystic Fibrosis Foundation TherapeuticsCompleted14 YearsN/ABoth75N/AUnited States
12NCT00333385
(ClinicalTrials.gov)
October 20012/6/2006Continuous Versus Short Infusions of Ceftazidime in Cystic FibrosisCystic Fibrosis;Pseudomonas Aeruginosa;Pulmonary ExacerbationDrug: ceftazidimeAssociation Nationale pour le Traitement à Domicile de l'Insuffisance RespiratoireVaincre la Mucoviscidose;GlaxoSmithKline;Baxter Healthcare Corporation;Roche Pharma AGTerminated8 YearsN/ABoth120Phase 4France